Attraction of the leading scientists to Russian institutions of higher learning, research organizations of the governmental academies of sciences, and governmental research centers of the Russian Federation

Laboratory for Experimental Immunology

About the Laboratory

This laboratory was established as part of a scientific research project supported with a monetary grant awarded by the Government of the Russian Federation under a grant competition designed to provide governmental support to scientific research projects implemented under the supervision of the world's leading scientists at Russian institutions of higher learning (Resolution of the RF Government No.220 of April 9, 2010).

Link to the official website - missing

Grant Agreement No.:
14.Z50.31.0008

Name of the institution of higher learning:
Lobachevsky State University of Nizhni Novgorod (UNN)

Fields of scientific research:
Biology, Medical Sciences

Project goal:

To carry out a comparative analysis of several new blockers of tumour necrosis factors (TNF)* and to create conditions for their subsequent production and clinical application.

Project objectives: 

- To develop new generation TNF blockers capable of pharmacologically neutralizing TNF solely from the principal source of pathogens, and to test them experimentally on mice.
- To test an experimental model of pharmacological blocking of human TNF using "humanized" arthritic mice and commercially available anti-TNF medications (Infliximab or Adalimumab, Etanercept and Certolizumab Pegol).
- To investigate TNF pathogenesis in autoimmune conditions using recently created "reporter" mice and lifetime imaging developed at the Medical Academy of the Nizhniy Novgorod State University.
- To create a platform for preclinical evaluation of several chimerized and humanized TNF antagonists based on antibodies.
- To design a panel of new bispecific TNF blockers based on single-domain camel antibodies that are able to block TNF on the surface of certain types of cells (e.g. macrophages or B-cells). To determine similarities and pharmacokinetics of new bispecific antibodies and evaluate their effectiveness in experimental conditions using humanized mice.
- To evaluate the effects of Etanercept/Enbrel as compared to those of Infliximab and Certolizumab Pegol upon systemic IgA levels and the composition of microbiota in humanized mice.

Anticipated results of the project: 

The project will help organize a self-sufficient experimental laboratory that in the nearest future will be able to solve – on a most advanced level – biomedical problems using mice-based models. The project seeks to obtain new experimental data on anti-TNF therapy using mice, results that are sufficient for publication in high-impact journals and presentation at important international conferences. A patent application will be submitted for a new anti-TNF medication.
Several new biomedical technologies, including unique models of health conditions in mice and antibody engineering technologies based on camel "nanobodies" will be transferred to the Nizhniy Novgorod State University.
The project entails training at least three undergraduate/graduate students who will be able to join the laboratory staff and continue conducting research at an international level after 2016.
The project also entails organizing a series of lectures on immunology and oncology at the Nizhniy Novgorod State University (it is anticipated that at least two Nobel Prize winners will take part in the delivery of the lectures). The project also seeks to contribute to the ongoing regular instruction process at the Nizhniy Novgorod State University.

Leading Scientist

 

Full Name: Nedospasov Sergey Arturovich

Link to the scientist's profile

Academic degree and title:
Doctoral degree in Biology, Corresponding member of Russian Academy of Sciences, Professor

Job Title:

Senior Researcher at the Experimental Medicine Laboratory at the Scientific Research Institute of Molecular Biology and Regional Ecology of Lobachevsky State University of Nizhny Novgorod,

Head of laboratory at the Institute of Molecular Biology named after V. A. Engelgardt of the Russian Academy of Sciences,

Head of the Department of Immunology of the Moscow State University named after M. V. Lomonosov,

Head of department at the Scientific Research Institute of Physical and Chemical Biology named after Belozersky under Lomonosov Moscow State University.

Fields of scientific interests:

Biology and physiology of cytokines – protein regulators of immunity and other important bodily functions.

Scientific Recognition:

The leading scientist pioneered in application of reverse genetics methods in biomedical research in Russia. He organized and has been spearheading the Department of Immunology of the Faculty of Biology of the Moscow State University named after M. V. Lomonosov and reads the principal course in immunology.

Back to top